celecoxib (DRGT-46)
/ Tavanta Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 10, 2019
DRGT completes a pivotal phase I trial; results confirm 6x faster attainment of maximum plasma levels for pain management compared to currently available COX-2 inhibitor
(GlobeNewswire)
- "Druggability Technologies Holdings…announced results from a pharmacokinetic study of their novel formulation of celecoxib (‘DRGT-46’), which achieves faster time to maximum plasma concentration (Tmax) compared to traditional celecoxib capsules….‘We are working to initiate a pivotal phase 3 program in adults with acute pain and continuing to explore other development options for both adult and pediatric populations.'"
New P3 trial • P1 data • PK/PD data
1 to 1
Of
1
Go to page
1